ArticleJournal of medical biochemistry2026
Correlation analysis of serum SERPINA3, CLEC2 and hs-CRP/ALB with major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in STEMI.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To examine the main adverse cardiovascular events that occur in individuals who have had an acute ST-segment elevation myocardial infarction (STEMI) after receiving percutaneous coronary intervention (PCI), such as serum C-type lectin domain family member 2 (CLEC2), serine protease inhibitor family member A3 (SERPINA3), and high-sensitivity C-reactive protein/albumin (hs-CRP/ALB) levels. Methods: The STEMI group included 132 patients who were observed for 1 year after hospitalisation between January 2023 and September 2024. The patients were divided into two groups: the MACE group and the non-MACE group, based on whether MACE came after PCI. Additionally, the control group consisted of 68 healthy individuals who were physically examined at the hospital during the same time period. Using an enzyme-linked immunosorbent test, the levels of serum CLEC2, SERPINA3, hs-CRP and ALB were measured in each research participant, and the hs-CRP to ALB ratio was computed. After PCI, multivariate logistic regression was used to examine variables associated with MACEs in STEMI patients. Receiver operating characteristic (ROC) curves were used to analyse the predictive value of single and combined detection of serum CLEC2, SERPINA3, and hs-CRP/ALB for MACEs in STEMI patients after PCI. Results: The incidence of MACE after PCI in 132 STEMI patients was 31.06% (41/132). The levels of serum CLEC2, SERPINA3 and hs-CRP/ALB in the STEMI group were significantly greater than those in the control group (P< 0.05). Independent risk factors for MACEs following PCI in STEMI patients included age >62 years, Killip grade > grade III, cardiac troponin I level >1.7 ng/mL, CLEC2 level >155 pg/mL, SERPINA3 level >350 ng/L, and hs-CRP/ALB >0.50 (P< 0.05), while left ventricular ejection fraction >50% was an independent protective factor. The area under the ROC curve (0.856) of the combined detection of serum CLEC2, SERPINA3, and hs-CRP/ALB for the prediction of MACEs in STEMI patients after PCI was greater than that of the individual detection of each index. Conclusions: Serum CLEC2 levels >155 pg/mL, SERPINA3 levels >350 ng/L, and hs-CRP/ALB>0.50 are closely related to the occurrence of MACEs in STEMI patients after PCI and can be used as auxiliary predictive indicators for the occurrence of MACEs in STEMI patients after PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.